Ai Kuzumi, MD, PhD; Satoshi Ebata, MD, PhD; Takemichi Fukasawa, MD, PhD; et al.
free access
JAMA Dermatol. 2023;159(4):374-383. doi:10.1001/jamadermatol.2022.6340
This cohort study evaluates the long-term outcomes after rituximab treatment for systemic sclerosis and identifies potential response markers.
Erika Yue Lee, MD; Christopher Knox, BSc; Elizabeth Jane Phillips, MD
free access
JAMA Dermatol. 2023;159(4):384-392. doi:10.1001/jamadermatol.2022.6378
This systematic review and meta-analysis of 38 studies including 2917 patients evaluates the prevalence of antibiotics associated with Stevens-Johnson syndrome and toxic epidermal necrolysis worldwide.
Emily Baumrin, MD; Laura X. Baker, MD; Michael Byrne, MD; et al.
free access
JAMA Dermatol. 2023;159(4):393-402. doi:10.1001/jamadermatol.2022.6624
This cohort study assesses the prognostic value of body surface area and National Institutes of Health Skin Score on survival outcomes stratified by erythema and sclerosis subtypes of chronic graft-vs-host disease.
Pascal Joly, MD, PhD; Audrey Lafon, MD; Estelle Houivet, MS; et al.
free access
JAMA Dermatol. 2023;159(4):403-410. doi:10.1001/jamadermatol.2022.6687
This randomized clinical trial evaluates the efficacy and tolerance of methotrexate alone or combined with low-dose prednisone in patients with chronic and recalcitrant alopecia areata totalis or universalis.
Arash Mostaghimi, MD, MPA, MPH; Wei Gao, MS, PhD; Markqayne Ray, PharmD, MBA; et al.
open access
JAMA Dermatol. 2023;159(4):411-418. doi:10.1001/jamadermatol.2023.0002
This cohort study examines the annual prevalence and incidence of alopecia areata and alopecia totalis/alopecia universalis in the US.
Nene Sy, BS; Nicole Mastacouris, BS; Andrew Strunk, MA; et al.
free access
JAMA Dermatol. 2023;159(4):419-423. doi:10.1001/jamadermatol.2023.0016
This cross-sectional study examines the prevalence of alopecia areata, alopecia totalis, and alopecia universalis overall and among racial and ethnic groups in the US.